Upregulation of proinflammatory cytokines/chemokines in brain ("neuroinflammation") accompanies brain injury/disease and systemic infections. Following nerve terminal damage after acute exposure to dopaminergic neurotoxicant, methamphetamine (METH), we documented elevated neuroinflammation, which may serve as a modulator or mediator of astroglial/microglial activation. Activated glia (associated with all types of brain injury) may be neuroprotective or exacerbate neural damage. Our prior genetic and pharmacological interventions have resulted in partial suppression of METH induced neuroinflammation without affecting neurotoxicity/astrogliosis. Here, mice were pretreated with the stress hormone corticosterone (CORT;400 mg/L drinking water) for 1 week or repeated in vivo stress for 5d, consisting of social reorganization and cage shaking. METH administration alone (20mg/kg,s.c.) caused significant increases in proinflammatory cytokine (TNFalpha,IL6,CCL2,IL1beta,LIF,OSM) mRNA expression in striatum at 12h. By 72h marked astrocytic hypertrophy (GFAP protein/immunohistochemistry(IHC)), microglial activation (isolectin IHC) and dopaminergic nerve terminal damage (TH protein /IHC) was observed in striatum. Chronic CORT pretreatment caused exacerbated inflammation, astrocyte hypertrophy and microglial activation after METH exposure in the striatum, hippocampus and cortex. Of note, chronic CORT pretreatment exacerbated METH-induced decreases in TH protein (to 10% of control) in striatum. However, repeated in vivo stress exposure completely blocked striatal dopaminergic neurotoxicity and reduced the neuroinflammatory response to METH. As the levels of chronic CORT approached or exceeded those associated with high physiological stress, our data suggest that chronic CORT therapy or sustained physiological stress sensitizes the CNS neuroinflammatory and neurotoxic responses to METH. Also, more severe or prolonged in vivo stressor application may be required to produce priming of the CNS similar to exogenous CORT.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.